Gynecological Cancer
Tailor treatment through targeted, next-generation sequencing
Mayo Clinic Laboratories’ MayoComplete gynecological cancer panels use next-generation sequencing to evaluate genes with known relevance to diagnosis, prognosis, and treatment of uterine, ovarian, and endometrial cancers. An integrated team of gynecologic clinicians, geneticists, and genetic counselors carefully designed our panels to include only clinically actionable genes.
Gynecological Cancer Test menu
Next-generation sequencing panels
Patient-centric, cost-effective, and efficient, our panels provide a detailed picture of a patient’s illness to help understand the best path forward. Identifying a pathogenic variant can also support familial screening and genetic counseling for a variety of hereditary cancer syndromes.
Key testing
- MCGYN | MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor
- Provides diagnostic, prognostic, and therapeutic insights by assessing 49 genes for somatic mutations and microsatellite instability status (MSI).
- Useful in diagnosing granulosa cell and rare ovarian tumors.
- MCECP | MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor
- Provides diagnostic, prognostic, and therapeutic insights by assessing 19 genes for somatic mutations and MSI.
- MCOCP | MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor
- Provides therapeutic insights based on assessment of 14 genes.
- Identifies BRCA1, BRCA2, and additional DNA damage response genes.
Highlights
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and about one-third of patients respond to the new medication.
Endometrial cancer affects thousands annually and ranks as the fourth most common cancer among women in the United States. At the forefront of innovative discoveries in endometrial cancer diagnostics are Mayo Clinic's Department of Laboratory Medicine and Pathology consultants. Sounak Gupta, M.B.B.S., Ph.D., vice chair of Oncology Practice for the Division of Laboratory Genetics and Genomics; Maryam Shahi, M.D., senior consultant for Anatomic Pathology; and Andrea Mariani, M.D., M.S., division chair of Gynecologic Surgery, explore the critical significance of molecular profiling and collaborative efforts driving these innovations, highlighting Mayo Clinic’s revolutionary influence on patient care.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.